Publications (Clicking on the reprint icon will take you to the publication reprint.)

Chimeric phage lysins act synergistically with lysostaphin to kill mastitis causing staphylococcus aureus in murine mammary glands - (Peer Reviewed Journal)

Schmelcher, M., Powell, A.M., Becker, S.C., Camp, M.J., Donovan, D.M. 2012. Chimeric phage lysins act synergistically with lysostaphin to kill mastitis causing staphylococcus aureus in murine mammary glands. Applied and Environmental Microbiology. 78(7):2297-305.

Lysostaphin: molecular changes that preserve staphylolytic activity. - (Proceedings) - (20-Feb-11)

LysK, the enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards stabilization - (Review Article)

Filatova, L.Y., Becker, S.C., Donovan, D.M., Gladilin, A.K., Klyachko, N.L. 2010. LysK, the enzyme lysing Staphylococcus aureus cells: specific kinetic features and approaches towards stabilization. Biochimie. 92(5):507-13.

Engineering Antimicrobials Refractory to Resistance - (Abstract Only)

Becker, S.C., Pohl, C.S., Mohammadi, H., Schmelcher, M., Foster Frey, J.A., Lease, R.A., Don, S., Baker, J.R., Pritchard, D.G., Donovan, D.M. 2009. Engineering Antimicrobials Refractory to Resistance. Evergreen International Phage Meeting.

Peptidoglycan hydrolase fusion to protein transduction domains kill intracellular staphylococci. - (Abstract Only)

Becker, S.C., Foster Frey, J.A., Willard, R.R., Lease, R.A., Almeida, R., Marriott, I., Dong, S., Baker, J.R., Pritchard, D.G., Donovan, D.M. 2009. Peptidoglycan hydrolase fusion to protein transduction domains kill intracellular staphylococci. Evergreen International Phage Meeting.

Peptidoglycan Hydrolases for Control of Mastitis Pathogens - (Abstract Only)

Schmelcher, M., Becker, S.C., Foster Frey, J.A., Donovan, D.M. 2009. Peptidoglycan Hydrolases for Control of Mastitis Pathogens. Evergreen International Phage Meeting.

Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer increased staphylolytic and streptolytic activity to a streptococcal prophage endolysin domain. - (Peer Reviewed Journal)

Becker, S.C., Foster-Frey, J., Stodola, A.J., Anacker, D., Donovan, D.M., 2009. Differentially conserved staphylococcal SH3b_5 cell wall binding domains confer identical staphylolytic activity to a streptococcal prophage endolysin lytic domain. FEMS Immunology and Medical Microbiology. 443(1-2):32-41.

Antimicrobials for staphylococcal pathogens that are refractory to resistance development - (Abstract Only)

Becker, S.C., Foster Frey, J.A., Willard, R.R., Lease, R.A., Almeida, R., Marriott, I., Dong, S., Pritchard, D.G., Donovan, D.M. 2009. Antimicrobials for staphylococcal pathogens that are refractory to resistance development. International Symposium on Antimicrobial Peptides.

Antimicrobials for mastitis causing pathogens that are refractory to resistance development - (Abstract Only)

Becker, S.C., Don, S., Baker, J.R., Foster Frey, J.A., Pritchard, D.G., Donovan, D.M. 2009. Antimicrobials for mastitis causing pathogens that are refractory to resistance development. BARC Poster Day.

Peptidoglycan hydrolase enzyme fusions are uniquely suited for treating multi-drug resistant pathogens - (Review Article)

Donovan, D.M., Becker, S.C., Dong, S., Baker, J.R., Foster Frey, J.A., Pritchard, D.G. 2009. Peptidoglycan hydrolase enzyme fusions are uniquely suited for treating multi-drug resistant pathogens. Biotech International 21(2):6-10.

LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. - (Peer Reviewed Journal)

Becker, S.C., Don, S., Baker, J.R., Foster Frey, J.A., Pritchard, D.G., Donovan, D.M. 2009. LysK CHAP endopeptidase domain is required for lysis of live staphylococcal cells. FEMS Microbiology Letter. 294(1):52-60.

SH3b Cell wall binding domains can enhance anti-staphylococcal activity of endolysin lytic domains. - (Abstract Only) - (10-Jul-08)

Engineering Antimicrobials that are Refractory to Resistance Development. - (Abstract Only)

Donovan, D.M., Becker, S.C. 2009. Engineering Antimicrobials that are Refractory to Resistance Development. Meeting Abstract.

Engineering MRSA antimicrobials that are refractory to resistance development - (Abstract Only)

Becker, S.C., Donovan, D.M., Foster Frey, J.A. 2008. Engineering MRSA antimicrobials that are refractory to resistance development. BARC Poster Day.